Feb 22, 2025 In a major regulatory move, India's Central Drug Regulator (CDSCO) have ordered the immediate withdrawal of manufacturing and export permissions for all Tapentadol-Carisoprodol combinations. This decisive action comes in response to growing concerns over their misuse…
Recent Post
- CDSCO Notifies Final Guidance Document on Medical Device Software (MDSW)
- When a “+” Sign Isn’t Just a Plus
- DCC intends to tighten control on manufacturing and supply of printed packaging materials used for drugs
- High-Alcohol Oral Formulations Move Into Schedule H1
- DCC Recommends Comprehensive Regulatory Mechanism to Curb Unapproved Drugs and FDCs
